Symbols / IMTX
IMTX Chart
About
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.38B |
| Enterprise Value | 829.14M | Income | -119.99M | Sales | 84.76M |
| Book/sh | 4.04 | Cash/sh | 3.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 645 | IPO | — |
| P/E | — | Forward P/E | -5.57 | PEG | — |
| P/S | 16.24 | P/B | 2.54 | P/C | — |
| EV/EBITDA | -6.21 | EV/Sales | 9.78 | Quick Ratio | 6.99 |
| Current Ratio | 7.36 | Debt/Eq | 3.93 | LT Debt/Eq | — |
| EPS (ttm) | -1.10 | EPS next Y | -1.84 | EPS Growth | — |
| Revenue Growth | -89.70% | Earnings | 2026-03-26 | ROA | -16.23% |
| ROE | -30.03% | ROIC | — | Gross Margin | -107.70% |
| Oper. Margin | -10.53% | Profit Margin | -141.57% | Shs Outstand | 134.06M |
| Shs Float | 59.93M | Short Float | 5.00% | Short Ratio | 14.45 |
| Short Interest | — | 52W High | 12.41 | 52W Low | 3.30 |
| Beta | 1.36 | Avg Volume | 456.77K | Volume | 115.64K |
| Target Price | $19.38 | Recom | Strong_buy | Prev Close | $10.23 |
| Price | $10.27 | Change | 0.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.38
Mean price target
2. Current target
$10.27
Latest analyst target
3. DCF / Fair value
$-18.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.27
Low
$11.00
High
$25.00
Mean
$19.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-11-19 | main | Mizuho | Outperform → Outperform | $23 |
| 2025-11-18 | main | Guggenheim | Buy → Buy | $19 |
| 2025-09-18 | init | Guggenheim | — → Buy | $16 |
| 2025-05-28 | init | Deutsche Bank | — → Buy | $10 |
| 2025-04-01 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-11-19 | main | B of A Securities | Buy → Buy | $15 |
| 2024-10-07 | init | Piper Sandler | — → Overweight | $19 |
| 2024-09-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-09-05 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-05-16 | main | Mizuho | Buy → Buy | $16 |
| 2023-11-02 | init | Cantor Fitzgerald | — → Overweight | — |
| 2023-03-31 | init | Mizuho | — → Buy | $12 |
| 2023-03-23 | main | Chardan Capital | — → Buy | $25 |
| 2022-08-10 | main | Chardan Capital | — → Buy | $28 |
| 2022-06-03 | main | SVB Leerink | — → Outperform | $26 |
| 2022-03-24 | main | SVB Leerink | — → Outperform | $25 |
| 2021-07-15 | main | SVB Leerink | — → Outperform | $27 |
| 2021-03-17 | main | SVB Leerink | — → Outperform | $26 |
| 2020-09-22 | init | Goldman Sachs | — → Buy | $17 |
- Immatics (NASDAQ:IMTX) Shares Down 5% - Time to Sell? - MarketBeat Fri, 20 Feb 2026 19
- Liquidity Mapping Around (IMTX) Price Events - Stock Traders Daily Fri, 20 Feb 2026 13
- Immatics (NASDAQ: IMTX) to sell 12,500,000 shares at $10.00 in underwritten offering - Stock Titan Fri, 05 Dec 2025 08
- Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha hu, 25 Dec 2025 08
- What Immatics (IMTX)'s Melanoma Orphan Drug Designation Means For Shareholders - simplywall.st Sat, 14 Feb 2026 08
- Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Mon, 17 Nov 2025 08
- Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering - Quiver Quantitative Fri, 05 Dec 2025 08
- Immatics Announces $125 Million Underwritten Offering - GlobeNewswire Fri, 05 Dec 2025 08
- Immatics (NASDAQ: IMTX) reports 46% ORR for IMA203CD8 in Phase 1a PRAME solid tumors - Stock Titan hu, 11 Dec 2025 08
- Revenues Not Telling The Story For Immatics N.V. (NASDAQ:IMTX) After Shares Rise 28% - simplywall.st Fri, 05 Dec 2025 08
- Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Should You Buy? - MarketBeat ue, 10 Feb 2026 08
- Immatics (NasdaqCM:IMTX) Valuation Check After Follow-On Share Offering Announcement - Yahoo Finance Fri, 05 Dec 2025 08
- Why (IMTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily Mon, 09 Feb 2026 08
- Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 (NASDAQ:IMTX) - Seeking Alpha Fri, 10 Oct 2025 07
- Immatics N.V. Appoints Venkat Ramanan, Ph.D. as Chief Financial Officer - Quiver Quantitative Wed, 01 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 10.29M | -200.26K | 3.63M | 0.00 |
| TaxRateForCalcs | 0.29 | 0.02 | 0.34 | 0.00 |
| NormalizedEBITDA | -1.39M | -80.65M | 39.40M | -80.90M |
| TotalUnusualItems | 35.85M | -8.28M | 10.64M | -6.61M |
| TotalUnusualItemsExcludingGoodwill | 35.85M | -8.28M | 10.64M | -6.61M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 15.22M | -94.65M | 27.70M | -93.33M |
| ReconciledDepreciation | 12.22M | 7.23M | 6.97M | 5.26M |
| EBITDA | 34.46M | -88.93M | 50.04M | -87.51M |
| EBIT | 22.23M | -96.16M | 43.07M | -92.77M |
| NetInterestIncome | 24.11M | 13.01M | 1.44M | -433.00K |
| InterestExpense | 886.00K | 831.00K | 1.04M | 566.00K |
| InterestIncome | 25.00M | 13.85M | 2.48M | 133.00K |
| NormalizedIncome | -10.34M | -86.57M | 20.69M | -86.73M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 15.22M | -94.65M | 27.70M | -93.33M |
| TotalExpenses | 194.45M | 155.72M | 142.88M | 121.06M |
| TotalOperatingIncomeAsReported | -38.62M | -101.72M | 29.95M | -86.29M |
| DilutedAverageShares | 106.80M | 80.55M | 68.21M | 62.91M |
| BasicAverageShares | 105.74M | 80.55M | 66.99M | 62.91M |
| DilutedEPS | 0.14 | -1.18 | 0.55 | -1.48 |
| BasicEPS | 0.14 | -1.18 | 0.56 | -1.48 |
| DilutedNIAvailtoComStockholders | 15.22M | -94.65M | 27.70M | -93.33M |
| NetIncomeCommonStockholders | 15.22M | -94.65M | 27.70M | -93.33M |
| NetIncome | 15.22M | -94.65M | 27.70M | -93.33M |
| MinorityInterests | 0.00 | 0.00 | ||
| NetIncomeIncludingNoncontrollingInterests | 15.22M | -94.65M | 27.70M | -93.33M |
| NetIncomeContinuousOperations | 15.22M | -94.65M | 27.70M | -93.33M |
| TaxProvision | 6.13M | -2.35M | 14.33M | 0.00 |
| PretaxIncome | 21.35M | -96.99M | 42.04M | -93.33M |
| OtherIncomeExpense | 35.85M | -8.28M | 10.64M | -6.61M |
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | ||
| GainOnSaleOfSecurity | 35.85M | -8.28M | 10.64M | -6.61M |
| NetNonOperatingInterestIncomeExpense | 24.11M | 13.01M | 1.44M | -433.00K |
| InterestExpenseNonOperating | 886.00K | 831.00K | 1.04M | 566.00K |
| InterestIncomeNonOperating | 25.00M | 13.85M | 2.48M | 133.00K |
| OperatingIncome | -38.62M | -101.72M | 29.95M | -86.29M |
| OperatingExpense | 194.45M | 155.72M | 142.88M | 121.06M |
| OtherOperatingExpenses | -78.00K | -1.14M | -26.00K | -325.00K |
| ResearchAndDevelopment | 148.08M | 118.66M | 106.78M | 87.57M |
| SellingGeneralAndAdministration | 46.45M | 38.20M | 36.12M | 33.81M |
| GeneralAndAdministrativeExpense | 46.45M | 38.20M | 36.12M | 33.81M |
| OtherGandA | 22.96M | 16.42M | 36.12M | 33.81M |
| SalariesAndWages | 23.48M | 21.78M | 20.92M | 19.48M |
| TotalRevenue | 155.84M | 54.00M | 172.83M | 34.76M |
| OperatingRevenue | 155.84M | 54.00M | 172.83M | 34.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 121.55M | 84.66M | 76.67M | 62.93M |
| ShareIssued | 121.55M | 84.66M | 76.67M | 62.93M |
| TotalDebt | 16.20M | 15.40M | 14.56M | 9.85M |
| TangibleBookValue | 573.21M | 216.09M | 201.72M | 22.75M |
| InvestedCapital | 574.84M | 217.62M | 203.35M | 24.06M |
| WorkingCapital | 561.57M | 292.82M | 270.70M | 57.06M |
| NetTangibleAssets | 573.21M | 216.09M | 201.72M | 22.75M |
| CapitalLeaseObligations | 16.20M | 15.40M | 14.56M | 9.85M |
| CommonStockEquity | 574.84M | 217.62M | 203.35M | 24.06M |
| TotalCapitalization | 574.84M | 217.62M | 203.35M | 24.06M |
| TotalEquityGrossMinorityInterest | 574.84M | 217.62M | 203.35M | 24.06M |
| StockholdersEquity | 574.84M | 217.62M | 203.35M | 24.06M |
| GainsLossesNotAffectingRetainedEarnings | 1.03M | -1.64M | -1.48M | -3.94M |
| OtherEquityAdjustments | 1.03M | -1.64M | -1.48M | -3.94M |
| RetainedEarnings | -589.54M | -604.76M | -510.11M | -537.81M |
| AdditionalPaidInCapital | 1.16B | 823.17M | 714.18M | 565.19M |
| CapitalStock | 1.22M | 847.00K | 767.00K | 629.00K |
| CommonStock | 1.22M | 847.00K | 767.00K | 629.00K |
| TotalLiabilitiesNetMinorityInterest | 121.30M | 292.35M | 204.47M | 150.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 53.32M | 135.79M | 98.02M | 55.44M |
| OtherNonCurrentLiabilities | 4.00K | 42.00K | 68.00K | |
| NonCurrentDeferredLiabilities | 39.97M | 122.99M | 85.57M | 48.23M |
| NonCurrentDeferredRevenue | 34.16M | 115.53M | 75.76M | 48.23M |
| NonCurrentDeferredTaxesLiabilities | 5.80M | 7.47M | 9.81M | |
| LongTermDebtAndCapitalLeaseObligation | 13.35M | 12.80M | 12.40M | 7.14M |
| LongTermCapitalLeaseObligation | 13.35M | 12.80M | 12.40M | 7.14M |
| CurrentLiabilities | 67.99M | 156.55M | 106.45M | 95.15M |
| OtherCurrentLiabilities | 3.19M | 19.21M | 26.28M | 28.04M |
| CurrentDeferredLiabilities | 35.91M | 100.40M | 64.96M | 50.40M |
| CurrentDeferredRevenue | 35.91M | 100.40M | 64.96M | 50.40M |
| CurrentDebtAndCapitalLeaseObligation | 2.85M | 2.60M | 2.16M | 2.71M |
| CurrentCapitalLeaseObligation | 2.85M | 2.60M | 2.16M | 2.71M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.58M | 1.28M | 806.00K | |
| CurrentProvisions | 51.00K | |||
| PayablesAndAccruedExpenses | 24.46M | 33.06M | 13.06M | 13.99M |
| CurrentAccruedExpenses | 10.58M | 17.54M | 9.71M | 9.22M |
| Payables | 13.88M | 15.52M | 13.06M | 4.77M |
| TotalTaxPayable | 3.77M | 7.86M | 7.72M | 1.76M |
| IncomeTaxPayable | 1.76M | 4.30M | 4.30M | 0.00 |
| AccountsPayable | 10.11M | 7.67M | 13.06M | 3.01M |
| TotalAssets | 696.15M | 509.96M | 407.82M | 174.65M |
| TotalNonCurrentAssets | 66.59M | 60.59M | 30.67M | 22.44M |
| OtherNonCurrentAssets | 917.00K | 603.00K | 2.54M | |
| NonCurrentPrepaidAssets | 333.00K | 1.41M | 1.91M | 636.00K |
| GoodwillAndOtherIntangibleAssets | 1.63M | 1.52M | 1.63M | 1.31M |
| OtherIntangibleAssets | 1.63M | 1.52M | 1.63M | 1.31M |
| NetPPE | 63.71M | 57.05M | 26.49M | 20.49M |
| AccumulatedDepreciation | -32.06M | -22.86M | -20.48M | -17.25M |
| GrossPPE | 95.78M | 79.92M | 46.97M | 37.74M |
| Leases | 31.42M | 25.41M | 3.84M | |
| OtherProperties | 38.48M | 30.61M | 35.47M | 20.51M |
| MachineryFurnitureEquipment | 12.73M | 11.05M | 7.67M | 8.21M |
| BuildingsAndImprovements | 13.15M | 12.85M | 12.41M | 9.03M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 629.55M | 449.37M | 377.15M | 152.21M |
| OtherCurrentAssets | 6.31M | 7.12M | 13.84M | 950.00K |
| HedgingAssetsCurrent | 0.00 | |||
| PrepaidAssets | 12.05M | 10.62M | 10.45M | 3.78M |
| Receivables | 6.75M | 5.74M | 1.11M | 2.36M |
| OtherReceivables | 762.00K | |||
| TaxesReceivable | 888.00K | 1.64M | 1.03M | 915.00K |
| AccountsReceivable | 5.86M | 4.09M | 1.11M | 682.00K |
| CashCashEquivalentsAndShortTermInvestments | 604.45M | 425.89M | 362.20M | 145.12M |
| OtherShortTermInvestments | 367.70M | 207.42M | 213.69M | 12.12M |
| CashAndCashEquivalents | 236.75M | 218.47M | 148.52M | 132.99M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -174.51M | -12.73M | 93.92M | -90.40M |
| RepaymentOfDebt | -2.01M | -3.85M | -2.84M | -2.71M |
| IssuanceOfCapitalStock | 343.01M | 90.40M | 134.48M | 94.00K |
| CapitalExpenditure | -16.48M | -30.96M | -6.21M | -5.66M |
| EndCashPosition | 236.75M | 218.47M | 148.52M | 132.99M |
| BeginningCashPosition | 218.47M | 148.52M | 132.99M | 207.53M |
| EffectOfExchangeRateChanges | 9.01M | -1.40M | 1.48M | 5.33M |
| ChangesInCash | 9.27M | 71.36M | 14.05M | -79.87M |
| FinancingCashFlow | 319.68M | 84.52M | 123.71M | -2.61M |
| CashFlowFromContinuingFinancingActivities | 319.68M | 84.52M | 123.71M | -2.61M |
| NetOtherFinancingCharges | -21.31M | -2.04M | -7.93M | |
| NetCommonStockIssuance | 343.01M | 90.40M | 134.48M | 94.00K |
| CommonStockIssuance | 343.01M | 90.40M | 134.48M | 94.00K |
| NetIssuancePaymentsOfDebt | -2.01M | -3.85M | -2.84M | -2.71M |
| NetLongTermDebtIssuance | -2.01M | -3.85M | -2.84M | -2.71M |
| LongTermDebtPayments | -2.01M | -3.85M | -2.84M | -2.71M |
| InvestingCashFlow | -152.39M | -31.39M | -209.79M | 7.49M |
| CashFlowFromContinuingInvestingActivities | -152.39M | -31.39M | -209.79M | 7.49M |
| NetInvestmentPurchaseAndSale | -135.91M | -581.00K | -203.63M | 13.15M |
| SaleOfInvestment | 314.44M | 414.74M | 12.70M | 24.45M |
| PurchaseOfInvestment | -450.35M | -415.32M | -216.32M | -11.30M |
| NetIntangiblesPurchaseAndSale | -208.00K | -158.00K | -477.00K | -551.00K |
| PurchaseOfIntangibles | -208.00K | -158.00K | -477.00K | -551.00K |
| NetPPEPurchaseAndSale | -16.27M | -30.65M | -5.69M | -5.11M |
| SaleOfPPE | 2.00K | 150.00K | 52.00K | 0.00 |
| PurchaseOfPPE | -16.27M | -30.80M | -5.74M | -5.11M |
| OperatingCashFlow | -158.03M | 18.23M | 100.13M | -84.75M |
| CashFlowFromContinuingOperatingActivities | -158.03M | 18.23M | 100.13M | -84.75M |
| TaxesRefundPaid | 0.00 | 0.00 | -224.00K | 0.00 |
| InterestReceivedCFO | 15.61M | 10.17M | 1.65M | 175.00K |
| InterestPaidCFO | -886.00K | -290.00K | -695.00K | -566.00K |
| ChangeInWorkingCapital | -163.88M | 81.63M | 37.26M | -31.70M |
| ChangeInOtherWorkingCapital | -160.05M | 86.00M | 45.56M | -31.78M |
| ChangeInOtherCurrentAssets | -2.06M | -1.39M | -7.87M | -483.00K |
| ChangeInPayablesAndAccruedExpense | -31.78M | |||
| ChangeInPayable | -31.78M | |||
| ChangeInAccountPayable | -31.78M | |||
| ChangeInReceivables | -1.76M | -2.98M | -429.00K | 569.00K |
| ChangesInAccountReceivables | -1.76M | -2.98M | -429.00K | 569.00K |
| OtherNonCashItems | -24.11M | -13.01M | -1.44M | 433.00K |
| StockBasedCompensation | 17.64M | 20.70M | 22.57M | 26.40M |
| DeferredTax | 6.13M | -2.35M | 14.33M | 0.00 |
| DeferredIncomeTax | 6.13M | -2.35M | 14.33M | 0.00 |
| DepreciationAmortizationDepletion | 12.22M | 7.23M | 6.97M | 5.26M |
| DepreciationAndAmortization | 12.22M | 7.23M | 6.97M | 5.26M |
| OperatingGainsLosses | -35.97M | 8.79M | -7.99M | 8.58M |
| GainLossOnInvestmentSecurities | -17.26M | 2.08M | -10.95M | 10.99M |
| NetForeignCurrencyExchangeGainLoss | -18.71M | 6.86M | 2.95M | -2.41M |
| GainLossOnSaleOfPPE | 1.00K | -150.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | 15.22M | -94.65M | 27.70M | -93.33M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for IMTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|